DOCSLIB.ORG

US5434163.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
US5434163.Pdf ||||||||||||||| US005434163A United States Patent 19 11) Patent Number: 5,434,163 Edlind et al. 45 Date of Patent: Jul.18, 1995 54 TREATMENT OF CRYPTOCOCCUS 56 References Cited NEOFORMANS INFECTION U.S. PATENT DOCUMENTS Edlin 3,745,187 7/1973 Naguchi et al. .................... 514/310 75 Inventors: PE F.Y.Eth of 3,769,308 10/1973 Kohimoto et al. ................... 514/310 Pa 9 s 4,725,605 2/1988 Crossley et al. .................... 514/338 4,794,123 12/1988 Crossley et al. .................... 514/232 4,863,945 9/1989 Crossley et al. .................... 514/393 73 Assignee: The Medical College of Pennsylvania, 4,952,589 8/1990 Brown ................................. 514/310 Philadelphia, Pa. 5,061,715 10/1991 Sunkara ............................... 514/34 5,151,426 8/1991 Bellene ................................ 514/262 21 Appl. No.: 62,444 5,200,417 4/1993 Brown et al. ....................... 514/310 Primary Examiner-Werren B. Lone 22 Filed: May 14, 1993 Attorney, Agent, or Firm-Janice E. Williams; Edward T. Lentz 51 Int. Cl. .............................................. A61K 3/47 I52) U.S. Cl. ................................. sia/30.5/268, 7 ABSTRACT 514/393; 514/395; 514/365; 514/31; 546/143; A method of treatment of Cryptococcus neoformans in 546/144; 546/145; 546/194; 546/201; 546/210; fection by administering to a patient in need thereof an 546/300 effective amount of a benzimidazile compound. 58 Field of Search ..................... 514/310, 232, 226.8, 514/393; 546/143, 144, 145, 194, 201, 210, 300 6 Claims, No Drawings 5,434,163 1. 2 maceutical composition such as a tablet using standard TREATMENT OF CRYPTOCOCCUS formulation methods and techniques. NEOFORMANS INFECTION It is expected that the effective dosage of the benz imidazole anthelmintic compound when used to treat BACKGROUND OF THE INVENTION 5 the conditions disclosed herein will be in the range of The present invention relates to the use of benzimid from 10 to 5000 mg per day, the compound being ad azole anthelmintics in the treatment of cryptococcal ministered in one or more discrete dosage units, one or infection including meningitis in particular in AIDS more times to achieve effective therapeutic levels in the patients, including individuals exhibiting HIV infection patient's cerebral spinal fluid, blood or other infection as well as auto-immune deficiency syndrome. 10 site for as long as is necessary to treat the condition and Cryptococcus neoformans is an encapsulated yeast that maintain the patient free of infection. The precise size, causes meningitis in AIDS patients. Currently recom per dose strength, frequency and duration of the dosage mended therapy includes amphotericin B--/-flucyto regimen will of course depend on the severity of the condition. sine. Toxicity is high and relapses are common. Benz 5 imidazoles are a large group of drugs used clinically for SPECIFIC EMBODIMENT OF THE INVENTION helminth infections and agriculturally as antifungal agents. There exists a need for additional or better ther The following example serves to illustrate specific aspects of the invention. Those skilled in the an with apies for treatment of Crytococcus neoformans. readily appreciate that the specific experiments detailed DETAILED DESCRIPTION OF THE 20 are only illustrative of the invention as described more INVENTION fully in the claims which follow thereafter. It has now been found that certain benzimidazole Eleven benzimidazole derivatives and amphotericin anthelmintics also have in vitro activity against Crypto B were tested in vitro against three isolates of Cryptococ coccus neoformans and as such are expected to be of use 25 cus neoformans. Drug concentrations inhibiting growth in the treatment of infections caused by this organism. 50% (IC50) were determined. More specifically the compounds are expected to be of Activity of benzimidazole derivatives and amphoteri use in the treatment of meningitis caused by this organ cin B against in vitro growth of three C. neoformans ism in particular in patients having AIDS. isolates are shown in Table I. Inhibitory concentrations In particular, fenbendazole, albendazole and meben 30 were determined by a broth dilution method. All values dazole have been found to exhibit high levels of activity are in pg/ml. Yeast were diluted from fresh overnight against the organism and are the preferred benzimid cultures grown in YEPD at 30° C. to a destiny of azole derivatives of the present invention. Those skilled 1 x 104 cells per ml YEPD, and 1 ml portions were in the an will recognize that other benzimidazole anthel aliquoted to culture tubes. Drags were added by two mintics and their derivatives may exhibit activity 35 fold serial dilution. Cultures were incubated at 30° C. against Cryptococcus neoformans as well and may be with shaking for 20 hrs. Cell numbers were determined substituted for the preferred embodiment of the present with a hemacytometer. invention. TABLE I The presently most preferred benzimidazoles for the U4 IU4 IU4 composition of the invention are fenbendazole methyl DRUG IC50 IC90 IC50 IC90 IC50 IC90 5-(phenylthio)-1H-benzimidazol-2-ylcarbamate), alben Fenbendazole 0.019 O.028 0.01 0.014 (0.06 (0.016 dazole methyl 5-(n-propylthio)-1H-benzimidazol-2- Nocodazole 0.3 0.22 0.09 0.12 0.20 0.29 ylcarbamate and mebendazole. However, it is possible Parbendazole 0.16 0.23 0.16 0.23 0.16 0.22 Mebendazole 0.23 0.43 0.18 0.32 0.19 0.40 to substitute other known and commercially available 45 Albendazole 0.16 0.25 0.3 0.45 0.30 O.45 benzimidazoles or prodrugs which metabolize into a Oxibendazole 2.3 3.2 1.0 2. 1.4 2. suitable benzimidazole. Among such compounds are Carbendazim 2.0 3.6 1.5 2.0 1.6 2.3 oxibendazole methyl 5-(n-propoxy)-1H-benzimidazol Benomyl 2.3 3.7 2.8 3.8 2.0 3.5 2-ylcarbamate), oxfendazole methyl 5-(phenylsulfinyl)- Oxfendazole 2.5 > 4.0 3.2 > 4.0 2.8 > 4.0 Thiabendazole > 4.0 4.0 d 4.0 > 4.0 > 4.0 > 4.0 1H-benzimidazole-2-ylcarbamate, parbendazole, cam 50 Benzinidazole > 4.0 4.0 4.0 > 4.0 4.0 >40 bendazole, flubendazole, ricobendazole, luxabendazole Amphotericin 0.035 0.064 0.024 0.065 0.011 0.045 and others. These benzinidazole are commercially B available. Prodrugs which metabolize in vitro into selected Four derivatives were found to have moderately high benzimidazoles may also be employed to replace the 55 activity (IC90=0.2-0.5 ug/ml, IC50=0.1-0.3 ug/ml), preferred benzimidazoles in the compositions of this while one, fenbendazole was highly active (IC90=0.- invention. Among the known prodrugs are thiopha 02-0.03 ug/ml, ICso=0.1-0.2 pg/ml). This was 2 fold nates 1,2-phenylenebis (iminocarbonothioyl) biscar more active than amphotericin B. Ten additional clini bamic acid diethyl esters. See, for example, U.S. Pat. cal isolates of Cryptococcus neoformans were tested Nos. 3,745,187 and 3,769,308. Another prodrug which 60 against fenbendazole, mebendazole and albendazole; may be useful is Febantel, i.e., 2-(methoxyacetyl) ani no-4-(phenylthio)-phenyl)carbonimidoyl biscarbamic similar sensitivities were observed. acid dimethyl ester. Also useful may be the Netobimin TABLE II esters. These known compounds may also be prepared DRUG IC50 (range) IC90 (range) by known and conventional methods by one of skill in 65 fenbendazole 0.012-0.024 0.05-0.033 the art. albendazole 0.2-0.18 0.22-0.45 When used in the method of the invention, the benz mebendazole 0.12-0.31 0.22-0.45 imidazole compound is formulated in a standard phar 5,434,163 3 4 Activity of fenbendazole, albendazole, and meben TABLE III LC90 (ug/ml) dazole against in vitro growth often C. neoformans clini amphotericin cal isolates is shown in Table 2. All values are in ug/ml. 5 Isolate fenbendazole albendazole mebendazole B 1KR 0.06 0.92 1.3 0.51 IC50 and IC90 values were comparable to those pres 14116 0.07 2.1 2.0 0.54 ented in Table 1, and varied over a narrow range (ap In vitrocidal activities offenbendazole, albendazole, proximately two-fold). 10 mebendazole, and amphotericin B against two C. neo formans isolates are shown in Table 3. Cidal activity Cidal activity was tested for two isolates. LC90 values was estimated by plating cultures on drug-free medium following a 20 h. incubation in the presence of different were 1.2 ug/ml, LC50=0.3 to 1.4 ug/ml for alben drug concentrations. Activity is expressed as LC90, the dazole and mebendazole and 0.06-0.1 g/ml, 15 concentration resulting in 90% reduction in cell number relative to the starting (t=0) number. LCso=0.03 to 0.04 g/ml for fenbendazole; the latter Spontaneous resistance to 1 ug/ml fenbendazole oc curred at a frequency of <1X 10-7; the corresponding are about 9 to 13 fold lower than the values obtained for frequency for amphotericin B was approximately amphotericin B. 20 2X 10-6. 25 30 35 45 50 55 65 5,434,163 7 8 Alignment of 6-tubulin residues 107-260 is shown in The high inhibitory and cidal activities of certain Table 4. Dots represent identity to the CNBTB se benzimidazoles against C. neoformans suggest that this quence. Arrows indicate residues responsible for beno group may provide a new therapeutic approach to cryp myl or thiabendazole resistance in S. cerevisiae (R241 to tococcocal meningitis. The route of administration of H), N. crassa (F167 to Y), and A. nidulans (A165 to V; benzimidazoles is oral, a clear advantage over ampho E198 to D, N, or K; F200 to Y).
Load more

Recommended publications
  • Expert Review 2
    2021 Expert Committee on Selection and Use of Essential Medicines Application review I.1 Albendazole, mebendazole and praziquantel for the indication of treatment of (item number) taeniid cestode cysts Does the application adequately ☒ Yes address the issue of the public health ☐ need for the medicine? No ☐ Not applicable Comments: The larval stages of three taeniid cestode parasites, Echinococcus granulosus, Echinococcus multilocularis and Taenia solium, produce cysts in humans that are of medical relevance. The diseases caused by these parasitic cysts are called cystic echinococcosis (CE), alveolar echinococcosis (AE), and cysticercosis (being neurocysticercosis (NCC) the most common form) respectively, and they are recognised by WHO as neglected tropical diseases. NCC is mainly a disease of poverty that predominantly affects rural populations in Africa, Asia and Latin America. Access to diagnostic and treatment, to better manage epilepsy and other NCC is a challenge for the people affected in these communities due to the availability and costs of specialised diagnostic and care. Stigma and social discrimination also mean that many people try to “hide” the disease. Briefly summarize the role of the The only real options for treatment of CE are albendazole (ALB) and Mebendazole proposed medicine(s) relative to other (MEB). ALB is the drug of choice as it has better bioavailability. ALB is also preferred to therapeutic agents currently included in MEB, because MEB requires a higher dose and a higher pill burden, for example, an the Model List, or available in the adult patient would require 8 tablets/day of MEB compared with 2 tablets/day ALB. market. ALB and praziquantel ( PZQ) are the only drugs used for the antiparasitic treatment of NCC.
    [Show full text]
  • Pharmacological Significance of Heterocyclic 1H-Benzimidazole
    Tahlan et al. BMC Chemistry (2019) 13:101 https://doi.org/10.1186/s13065-019-0625-4 BMC Chemistry REVIEW Open Access Pharmacological signifcance of heterocyclic 1H-benzimidazole scafolds: a review Sumit Tahlan, Sanjiv Kumar and Balasubramanian Narasimhan* Abstract Heterocyclic compounds are inevitable in a numerous part of life sciences. These molecules perform various note- worthy functions in nature, medication and innovation. Nitrogen-containing heterocycles exceptionally azoles family are the matter of interest in synthesis attributable to the way that they happen pervasively in pharmacologically dynamic natural products, multipurpose arranged useful materials also profoundly powerful pharmaceuticals and agrochemicals. Benzimidazole moiety is the key building block for several heterocyclic scafolds that play central role in the biologically functioning of essential molecules. They are considered as promising class of bioactive scafolds encompassing diverse varieties of activities like antiprotozoal, antihelminthic, antimalarial, antiviral, anti-infammatory, antimicrobial, anti-mycobacterial and antiparasitic. Therefore in the present review we tried to compile the various pharmacological activities of diferent derivatives of heterocyclic benzimidazole moiety. Keywords: Benzimidazole derivatives, Antiprotozoal activity, Anti-infammatory activity, Antimalarial activity, Antimycobacterial activity, Antiviral activity, Anticancer activity Introduction acetylcholinesterase [4], antiprotozoal [5], anti-infam- Among heterocyclic pharmacophores, the benzimida- matory [6], analgesic [7], antihistaminic [8], antimalarial zole ring system is quite common. Tese substructures [9], antitubercular [10], anti-HIV [11] and antiviral [12]. are often called ‘privileged’ due to their wide recurrence Some of the already synthesized compounds from the in bioactive compounds [1]. Benzimidazole moiety is above mentioned feld have found very strong application a fusion of benzene and imidazole ring system at the 4 in medicine praxis.
    [Show full text]
  • ALBENDAZOLE (Extrapolation to All Ruminants)
    European Medicines Agency Veterinary Medicines and Inspections EMEA/MRL/865/03-FINAL June 2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE ALBENDAZOLE (Extrapolation to all ruminants) SUMMARY REPORT (3) 1. Albendazole is a benzimidazole carbamate, used for the treatment of gastrointestinal infestations with roundworms, lungworms and tapeworms and adult flukes of Fasciola hepatica. Albendazole is currently entered into Annex I of Council Regulation (EEC) No. 2377/90 in accordance with the following table: Pharmacologically Marker residue Animal MRLs Target Other active substance(s) species tissues provisions Albendazole Sum of albendazole Bovine, 100 µg/kg Muscle sulphoxide, ovine 100 µg/kg Fat albendazole sulphone 1000 µg/kg Liver and albendazole 2- 500 µg/kg Kidney amino sulphone 100 µg/kg Milk expressed as albendazole 2. In reviewing the availability of endo- and ectoparasiticides for sheep and goats, albendazole was considered for extrapolation from bovine and ovine species to all ruminants. The considerations and criteria leading to the identification of albendazole are described in the Position Paper Regarding Availability of Veterinary Medicines – Extrapolation of MRLs (EMEA/CVMP/457/03-FINAL). 3. The scientific justification for this extrapolation was assessed in accordance with the Notes for Guidance on Risk Analysis Approach for Residues of Veterinary Medicinal Products in Food of Animal Origin (EMEA/CVMP/187/00-FINAL) and on the Establishment of Maximum Residue Limits for Minor Animal Species (EMEA/CVMP/153a/97-FINAL). 4. In setting the ADI in the original assessment of albendazole, the data summarised on the paragraphs below were considered. 5. The mode of action of albendazole is by binding strongly with the tubulin in the cells of nematodes.
    [Show full text]
  • Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: a Tropnet Study
    Klinik für Infektiologie & Spitalhygiene Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study Andreas Neumayr, Mirjam Schunk, Caroline Theunissen, Marjan Van Esbroeck, Matthieu Mechain, Manuel Jesús Soriano Pérez, Kristine Mørch, Peter Sothmann, Esther Künzli, Camilla Rothe, Emmanuel Bottieau Journal Club 01.03.21 Andreas Neumayr Background on giardia treatment: • 1st-line treatment: 5-nitroimidazoles: metronidazole (1957), tinidazole, ornidazole, secnidazole • cure rate of 5NIs in 1st-line treatment: ~90% • in the last decade, an increase of 5NI-refractory giardia cases has been observed in travel medicine clinics across Europe: Hospital for Tropical Diseases, London: 2008: 15% --> 2013: 40% 70% of 5NI-refractory cases imported from India • 2nd-line treatment: effectiveness of a 2nd round with a 5NI: ~17% alternative drugs: albendazole, mebendazole, nitazoxanide, quinacrine, furazolidone, chloroquine, paromomycin 2012 TropNet member survey: 53 centres use 39 different treatment regimens, consisting of 7 different drugs in mono- or combination-therapy in various dosages and durations JC 01.03.21 Nabarro LE et al. Clin Microbiol Infect. 2015;21:791-6. • by 2013, there were only 13 reports of 2nd-line therapy for giardiasis (8 case series, 5 individual case reports): n=110 Cure rates Albendazole 6/32 18.7% Paromomycin 5/17 29.4% Nitazoxanide 2/5 40.0% Albendazole + 5-NI 42/53 79.2% Quinacrine 19/21 90.5% Quinacrine + 5-NI 14/14 100% Quinacrine + Paromomycin 2/2 100% • 2013: TropNet "GiardiaREF" study kick-off: Study on efficacy and tolerability of two 2nd-line regimens in nitroimidazole-refractory giardiasis: Quinacrine JC 01.03.21 Meltzer E et al.
    [Show full text]
  • Study Assessing Prices, Availability and Affordability of Children's
    Study assessing prices, availability and affordability of children’s medicine in Chhattisgarh, India Part of the Better Medicine for Children project Authors Dr Antony KR Virendra Jain Puni Kokho Dr Kamlesh Jain The salient findings and views expressed in this report are solely those of the authors. Please direct correspondence to the authors: ([email protected], [email protected] [email protected], [email protected]). This publication does not necessarily represent the decisions or policies of the World Health Organization. ii Contents Acknowledgements ........................................................................................... v Abbreviations ................................................................................................... vi Executive summary ......................................................................................... vii Medicine availability .............................................................................................vii Medicine costs ................................................................................................... viii Affordability of standard treatment regimens ........................................................... ix Price components survey ...................................................................................... ix Conclusion .......................................................................................................... x 1. Introduction .................................................................................................
    [Show full text]
  • Anthelmintic Activity of Yeast Particle-Encapsulated Terpenes
    molecules Article Anthelmintic Activity of Yeast Particle-Encapsulated Terpenes Zeynep Mirza 1, Ernesto R. Soto 1 , Yan Hu 1,2, Thanh-Thanh Nguyen 1, David Koch 1, Raffi V. Aroian 1 and Gary R. Ostroff 1,* 1 Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA; [email protected] (Z.M.); [email protected] (E.R.S.); [email protected] (Y.H.); [email protected] (T.-T.N.); [email protected] (D.K.); raffi[email protected] (R.V.A.) 2 Department of Biology, Worcester State University, Worcester, MA 01602, USA * Correspondence: gary.ostroff@umassmed.edu; Tel.: 508-856-1930 Academic Editor: Vaclav Vetvicka Received: 2 June 2020; Accepted: 24 June 2020; Published: 27 June 2020 Abstract: Soil-transmitted nematodes (STN) infect 1–2 billion of the poorest people worldwide. Only benzimidazoles are currently used in mass drug administration, with many instances of reduced activity. Terpenes are a class of compounds with anthelmintic activity. Thymol, a natural monoterpene phenol, was used to help eradicate hookworms in the U.S. South circa 1910. However, the use of terpenes as anthelmintics was discontinued because of adverse side effects associated with high doses and premature stomach absorption. Furthermore, the dose–response activity of specific terpenes against STNs has been understudied. Here we used hollow, porous yeast particles (YPs) to efficiently encapsulate (>95%) high levels of terpenes (52% w/w) and evaluated their anthelmintic activity on hookworms (Ancylostoma ceylanicum), a rodent parasite (Nippostrongylus brasiliensis), and whipworm (Trichuris muris). We identified YP–terpenes that were effective against all three parasites.
    [Show full text]
  • Valbazen ® (Albendazole)
    ® (albendazole oral suspension) Broad-Spectrum Dewormer Oral Suspension for Use in Cattle, Sheep, and Goats for removal and control of liver flukes, tapeworms, stomach worms (including 4th stage inhibited larvae of Ostertagia ostertagi), intestinal worms, and lungworms in cattle and sheep and for the treatment of adult liver flukes in nonlactating goats Active Ingredient Albendazole ............................. 11.36% (equivalent to 113.6 mg/mL) 1 L/33.8 fl oz (1 qt 1.8 fl oz) Approved by FDA under NADA # 110-048 40029175 ® (albendazole oral suspension) Broad-Spectrum Dewormer Oral Suspension for Use in Cattle, Sheep, and Goats for removal and control of liver Indications: flukes, tapeworms, stomach worms (including 4th stage inhibited larvae of Ostertagia Cattle and sheep: Valbazen is a broad-spectrum anthelmintic effective in the removal ostertagi), intestinal worms, and lungworms in cattle and sheep and for the treatment and control of liver flukes, tapeworms, stomach worms (including 4th stage inhibited of adult liver flukes in nonlactating goats larvae of Ostertagia ostertagi ), intestinal worms, and lungworms as indicated below. Active Ingredient: Goats: For the treatment of adult liver flukes in nonlactating goats. Albendazole .......................................................... 11.36% (Equivalent to 113.6 mg/mL) Parasite Cattle Sheep Goats Adult Liver Flukes Fasciola hepatica Fasciola hepatica, Fascioloides magna Fasciola hepatica Heads and Segments Moniezia benedeni, M. expansa Common Tapeworm (Moniezia expansa), Fringed Tapeworm of Tapeworms (Thysanosoma actinioides) Adult and 4th Stage Brown Stomach Worm, including 4th stage Brown Stomach Worm (Ostertagia circumcincta, Marshallagia Larvae of Stomach inhibited larvae (Ostertagia ostertagi), marshalli), Barber Pole Worm (Haemonchus contortus), Small Worms Barber Pole Worm (Haemonchus Stomach Worm (Trichostrongylus axei) contortus, H.
    [Show full text]
  • Albendazole: a Review of Anthelmintic Efficacy and Safety in Humans
    S113 Albendazole: a review of anthelmintic efficacy and safety in humans J.HORTON* Therapeutics (Tropical Medicine), SmithKline Beecham International, Brentford, Middlesex, United Kingdom TW8 9BD This comprehensive review briefly describes the history and pharmacology of albendazole as an anthelminthic drug and presents detailed summaries of the efficacy and safety of albendazole’s use as an anthelminthic in humans. Cure rates and % egg reduction rates are presented from studies published through March 1998 both for the recommended single dose of 400 mg for hookworm (separately for Necator americanus and Ancylostoma duodenale when possible), Ascaris lumbricoides, Trichuris trichiura, and Enterobius vermicularis and, in separate tables, for doses other than a single dose of 400 mg. Overall cure rates are also presented separately for studies involving only children 2–15 years. Similar tables are also provided for the recommended dose of 400 mg per day for 3 days in Strongyloides stercoralis, Taenia spp. and Hymenolepis nana infections and separately for other dose regimens. The remarkable safety record involving more than several hundred million patient exposures over a 20 year period is also documented, both with data on adverse experiences occurring in clinical trials and with those in the published literature and\or spontaneously reported to the company. The incidence of side effects reported in the published literature is very low, with only gastrointestinal side effects occurring with an overall frequency of just "1%. Albendazole’s unique broad-spectrum activity is exemplified in the overall cure rates calculated from studies employing the recommended doses for hookworm (78% in 68 studies: 92% for A. duodenale in 23 studies and 75% for N.
    [Show full text]
  • Structure–Activity Relationship Analysis of Benzimidazoles As Emerging Anti-Inflammatory Agents: an Overview
    pharmaceuticals Review Structure–Activity Relationship Analysis of Benzimidazoles as Emerging Anti-Inflammatory Agents: An Overview Ravichandran Veerasamy 1,2,*, Anitha Roy 3 , Rohini Karunakaran 4 and Harish Rajak 5 1 Pharmaceutical Chemistry Unit, Faculty of Pharmacy, AIMST University, Semeling 08100, Kedah, Malaysia 2 Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai 600077, Tamil Nadu, India 3 Department of Pharmacology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai 600077, Tamil Nadu, India; [email protected] 4 Faculty of Medicine, AIMST University, Semeling 08100, Kedah, Malaysia; [email protected] 5 SLT Institute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur 495009, India; [email protected] * Correspondence: [email protected] Abstract: A significant number of the anti-inflammatory drugs currently in use are becoming obso- lete. These are exceptionally hazardous for long-term use because of their possible unfavourable impacts. Subsequently, in the ebb-and-flow decade, analysts and researchers are engaged in devel- oping new anti-inflammatory drugs, and many such agents are in the later phases of clinical trials. Molecules with heterocyclic nuclei are similar to various natural antecedents, thus acquiring immense consideration from scientific experts and researchers. The arguably most adaptable heterocyclic cores are benzimidazoles containing nitrogen in a bicyclic scaffold. Numerous benzimidazole drugs are broadly used in the treatment of numerous diseases, showing promising therapeutic poten- Citation: Veerasamy, R.; Roy, A.; tial. Benzimidazole derivatives exert anti-inflammatory effects mainly by interacting with transient Karunakaran, R.; Rajak, H. receptor potential vanilloid-1, cannabinoid receptors, bradykinin receptors, specific cytokines, 5- Structure–Activity Relationship lipoxygenase activating protein and cyclooxygenase.
    [Show full text]
  • Comparative Genomics of the Major Parasitic Worms
    Comparative genomics of the major parasitic worms International Helminth Genomes Consortium Supplementary Information Introduction ............................................................................................................................... 4 Contributions from Consortium members ..................................................................................... 5 Methods .................................................................................................................................... 6 1 Sample collection and preparation ................................................................................................................. 6 2.1 Data production, Wellcome Trust Sanger Institute (WTSI) ........................................................................ 12 DNA template preparation and sequencing................................................................................................. 12 Genome assembly ........................................................................................................................................ 13 Assembly QC ................................................................................................................................................. 14 Gene prediction ............................................................................................................................................ 15 Contamination screening ............................................................................................................................
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Pharmacokinetics and Metabolism Studies of Antifilarial Drugs Derivatives of Benzimidazole Carbamate
    v PHARMACOKINETICS AND METABOLISM STUDIES OF ANTIFILARIAL DRUGS DERIVATIVES OF BENZIMIDAZOLE CARBAMATE by SURASH RAMANATHAN Thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy • .. November 1996 TABLE OF CONTENTS Page Numbers Acknowledgement... .. ii Publications ................................................................................... XII List of Conferences .............................................................................. xiii List of Abbreviation ............................................................................. xiv Abstrak ............................................................................................. xv Abstract. ........................................................................................... xvii Chapter 1: INTRODUCTION .................................................................. 1 1.1 General Introduction ......................................................... ... 1 1.2 The Pathology and Clinical Manifestation of Lymphatic Filarasis ............................................................................3 1.2.1 The filarial life cycle .................................................... .3 1.2.2 Clinical manifestation of lymphatic filariasis infection ............. 7 1.3 Chemotherapy.. of Antifilarial Drugs ............................................ 8 1.3.1 Introduction ............................................................... 8 1.3.2 DEC and ivermectin ..................................................... 9 1.3.3
    [Show full text]